Back to Results
First PageMeta Content
Pharmacology / Cinacalcet / Drugs / Quality-adjusted life year / Clinical trial / Secondary hyperparathyroidism / Amgen / Cost-effectiveness analysis / Pharmaceutical Benefits Scheme / Health / Medicine / Health economics


Document Date: 2015-03-23 21:11:42

Open Document

File Size: 33,06 KB

Share Result on Facebook

City

Adelaide / /

Company

PBAC / Amgen Australia Pty Ltd / /

Country

Australia / /

Currency

USD / /

Holiday

Commonwealth Day / /

IndustryTerm

targeted / revised utilities / patient / treatment algorithm / /

MedicalCondition

chronic kidney disease / Kidney Disease / sustained secondary hyperparathyroidism / stroke / /

MedicalTreatment

dialysis / /

Organization

National Prescribing Service / Highly Specialised Drugs Program Private Hospital Authority / Public Hospital Authority / /

Position

Minister / /

Product

Sensipar / /

ProvinceOrState

Tasmania / /

Technology

treatment algorithm / dialysis / /

SocialTag